A phase I clinical trial conducted by researchers at King's College London and mental healthcare company Compass Pathways, indicates that the drug psilocybin has no adverse effects. Psilocybin induces hallucinogenic symptoms, which may be advantageous for some suffering from chronic depression. Yourway is able to transport even controlled substances across our global network.